Provention Bio, Inc. (PRVB)

[sokol]

After more reading and reflection, I think you are right that the license payments do not matter. Relative to the cost of treatment, for whatever it is worth, this is what one commentator had to say:

“Provention along with several advocacy groups is working to expand disease awareness and screening. This will help drive the second wave of sales to the broader at-risk population.

After months of working with key opinion leaders, advocacy groups, payers, doctors, and patients, Provention has settled on a wholesale acquisition cost of $13,850 per vial of TZIELD. Its 14-day treatment regimen is administered to patients through an IV in an outpatient setting to start, and will eventually be available at home too. The total cost of one treatment regimen is $193,900.

This price point reflects the perceived value from all of the stakeholders, including the payers that were receptive to covering it at this cost, that this game-changing medicine brings to patients.”